Merck and Ridgeback Biotherapeutics Initiate Phase III Trial to Evaluate Molnupiravir for COVID-19

Merck and Ridgeback Biotherapeutics announced the initiation of the Phase III clinical trial to evaluate an investigational oral antiviral therapeutic for the prevention of COVID-19 infection.